// App-Quantinova.ai

: Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Robert Thomas Mccormack

  • Arturo Molina

  • Matthew Raymond Smith

  • Robert Dreicer

  • Fred Saad

  • Ronald De Wit

  • Karim Fizazi

  • Dana T. Aftab

  • Ana Limon

  • Martin Fleisher

  • Johann S. De Bono

  • Gary J. Kelloff

  • Glenn Heller

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Veridex LLC, Raritan, NJ

  • Sutro Biopharma, South San Francisco, CA

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • University of Virgina, Charlottesville, VA

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Exelixis, Inc, South San Francisco, CA

  • Takeda Oncology, Cambridge, MA.

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

  • Canada

  • Netherlands

  • France

  • United Kingdom

Companies

  • Veridex LLC

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved